Market Newsdesk

The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM, Mind Cure’s digital therapeutics platform.

VANCOUVER, BC, Jan. 12, 2021 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is pleased to announce the signing of a non-binding letter of intent (the “LOI“) for strategic investment and commercial cooperation with ATMA Journey Centers Inc. (“ATMA“), a Calgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient. The LOI is intended to help Mind Cure secure an equity position within ATMA, empowering the Company with access to a global release strategy for iSTRYM, as well as international locations for translational research on novel molecules and treatment protocols.

“ATMA’s clinicians possess a proven track record of advocacy and innovation driving toward the therapeutic benefits of psychedelic medicine for patients in the treatment of mental health and wellness. Mind Cure is extremely excited to join ATMA in the renaissance  that is disrupting mental health care by partnering with one of the pioneers in the therapeutic psychedelics industry,” said Kelsey Ramsden, President & CEO, Mind Cure. “With Mind Cure’s therapeutic tool, iSTRYM, along with ATMA’s pivotal achievement as the care provider for Canada’s most recent section 56(1) exempt patient, mental health care in Canada is making history. We are thrilled to work with the best-in-class to drive our focus on accelerating our research and technology platforms.”

Mind Cure’s partnership with ATMA is an exciting opportunity for researchers and therapists to participate in each of Mind Cure’s research programs focused on pain, neuroregeneration, migraines, and cluster headaches. The proposed investment will facilitate the syndication of Mind Cure’s psychedelic drug protocols and the use of Mind Cure’s proprietary technology, iSTRYM, to optimize treatment for ATMA clients.

The deployment of capital will also advance speed and scale for data enrichment of iSTRYM, providing the AI-driven platform with access to patient data as ATMA targets domestic and international healing and treatment centers.

“Psilocybin-assisted therapy offers healing and understanding that is unmatched by traditional methods. Patients dealing with end-of-life anxiety, pain, depression, trauma, and addiction have been at the mercy of ineffective and underwhelming treatments for much too long. The resources are here, and we are extremely grateful to be at the frontlines of this world-changing, innovative, and extremely alleviating solution, to help bring peace to sufferers,” said David Harder, co-CEO, ATMA Journey Centers Inc. “We are witnessing an inflection point for mental health treatment as the commitment to wellness in Canada takes a huge step forward.”

Pursuant to the LOI, the parties intend to negotiate the terms of definitive agreements (the “Definitive Agreements“), which will provide for, among other things an initial $500,000 investment by Mind Cure in ATMA, participation by Mind Cure in ATMA’s future financings, and the exclusive use of iSTRYM throughout ATMA’s business. There can be no assurance that the Definitive Agreements will be entered into or that the investment or commercial transactions will be completed on the terms proposed in the LOI or at all.

About ATMA Journey Centers Inc. and SYNTAC Institute

ATMA is a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. ATMA is the first private sector service provider in Canada to announce psychedelic-assisted therapy provision under the approval of Health Canada’s Section 56(1) exemption, which will allow ATMA to provide psilocybin-assisted therapy to those seeking psychedelic assisted therapy.

ATMA’s founding members, David Harder, Greg Habstritt, and Vu Tran, also founded SYNTAC Institute, a non-profit organization with the mission of bringing the healing and transformative power of psychedelic medicine and psychedelic-assisted therapy to Canadians. SYNTAC has been an influential participant in the Canadian psychedelic medicine industry and operates Catalyst Presents, a series of conferences and summits in Canada focused on psychedelics.

About Mind Cure Health Inc.

Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the conclusion of the transactions and negotiation of the Definitive Agreements contemplated by the LOI on the terms disclosed herein, or at all; ATMA conducting additional psychedelic-assisted therapy; the disruption of mental health care through psychedelic-based therapies; the development of iSTRYM and incorporation into ATMA’s business; the relationship with ATMA accelerating the development of Mind Cure’s research and technology platforms; participation of researchers and therapists in Mind Cure’s research programs; Mind Cure’s investment facilitating the syndication of Mind Cure’s psychedelic drug protocols and the development of those protocols; protocols and iSTRYM to optimize treatment for ATMA clients and driving greater access to patient data for the AI-driven digital therapeutics platform; the roll-out of domestic and international treatment centres by ATMA; the realization of an inflexion point for mental health treatment; and Mind Cure’s collection of data from ATMA’s section 56 exempt clients.

Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products and ATMA’s clinics in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; the partnership with ATMA will help Mind Cure achieve its business goals; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure’s industry and Mind Cure’s business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure’s investments, results of operations, financial condition, and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mind Cure’s partnership with ATMA may not help Mind Cure achieve its business goals; iSTRYM, and its database function may not be successfully developed or help to optimize protocols and enhance scientific research; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mind-cure-signs-loi-to-acquire-an-ownership-interest-in-psychedelic-treatment-center-atma-selected-by-section-56-exempt-patient-for-psilocybin-therapy-301205985.html

SOURCE Mind Cure Health Inc.

NEW YORK, Jan. 12, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Restaurant Brands International Inc. (“Restaurant Brands” or the “Company”) (NYSE: QSR) and certain of its officers.   The class action, filed in the United States District Court for the Central District of California, and docketed under 21-cv-00148, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired Restaurant Brands securities between April 29, 2019 and October 28, 2019, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Restaurant Brands securities during the Class Period, you have until February 19, 2021, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]
 

Restaurant Brands is one of the world’s largest restaurant chains with over 27,000 Tim Hortons, Burger King, and Popeyes restaurants in more than 100 countries and U.S. territories as of December 31, 2019. 

On April 24, 2018, Restaurant Brands announced a new strategy designed to improve performance within the Company’s Tim Hortons brand.  Specifically, the “Winning Together Plan” would focus on three key pillars: restaurant experience; product excellence; and brand communications.

On March 20, 2019, Restaurant Brands announced “Tims Rewards”—a new loyalty program for Tim Hortons customers in Canada.  Under the Tims Rewards program, customers would be eligible for a free hot brewed coffee, hot tea, or baked good after every seventh paid visit to a participating Tim Hortons restaurant.  On April 10, 2019, Restaurant Brands announced that it was expanding the Tims Rewards program to include customers in the U.S.

Throughout the Class Period, Defendants repeatedly touted the implementation and execution of the Company’s Winning Together Plan and Tims Rewards loyalty program.  On the heels of the Company touting the benefits of these initiatives, the Company completed two stock offerings on or about August 12, 2019, and September 5, 2019, collectively resulting in proceeds of approximately $3 billion to insiders.

This Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations.  Specifically, Defendants misrepresented and/or failed to disclose that: (i) the Company’s Winning Together Plan was failing to generate substantial, sustainable improvement within the Tim Hortons brand; (ii) the Tims Rewards loyalty program was not generating sustainable revenue growth as increased customer traffic was not offsetting promotional discounting; and (iii) as a result, Defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.

On October 28, 2019, mere weeks after the offerings were completed, investors learned the truth about Tim Hortons’ hyped growth initiatives when the Company announced disappointing financial results for the third quarter ended September 30, 2019.  Specifically, Defendants acknowledged that “results at Tim Hortons were not where we want them to be with global comparable sales dipping into negative territory” and admitted that “discounting [associated with Tims Rewards] is slightly more than offsetting the traffic levels, which is causing a little bit of softness in sales.”

On this news, the price of Restaurant Brands common shares declined $2.59 per share, or approximately 4%, from a close of $68.45 per share on October 25, 2019, to close at $65.86 per share on October 28, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-restaurant-brands-international-inc-and-certain-officers–qsr-301205957.html

SOURCE Pomerantz LLP

Key Highlights

• NEXE Innovations is launching its new in-house brand, XOMA Superfoods, to meet the growing needs of health- and environmentally conscious consumers.
• The first XOMA Superfoods SKU, a soluble micro-ground coffee fortified with MCT oil packaged in the NEXE Pod, will launch as a pilot in late January.
• NEXE plans to add more products, available for purchase online and through subscription, via a new direct to consumer e-commerce platform.

VANCOUVER, BC, Jan. 12, 2021 /PRNewswire/ – NEXE Innovations Inc. (TSXV: NEXE) (“NEXE” or the “Company”), a leader in plant-based materials science and advanced manufacturing technologies, is pleased to announce XOMA Superfoods, NEXE’s in-house coffee and superfoods brand, soon to go live at www.Xoma.ca. XOMA – derived from the Greek word for soil – allows the Company to meet its sustainability mandate, while providing our customers with the highest quality coffees and superfoods. NEXE plans to launch the first stock-keeping unit (SKU) under the XOMA Superfoods brand, a soluble micro-ground coffee fortified with MCT oil packaged in the NEXE Pod, as a pilot in late January 2021.

“XOMA Superfoods is the next logical step for NEXE,” said Company CEO Darren Footz. “Our innovative, plant-based technology means that customers can continue with their daily superfood and coffee consumption but can now enjoy the experience sustainably. XOMA offers high-quality, healthy products in our fully compostable packaging.”

NEXE plans to add more products, available for purchase online and through subscription, via a new direct to consumer (“DTC”) e-commerce platform. XOMA Superfoods will eventually include a wide range of healthy lifestyle products, which may include coffees, superfood creamers, coconut oil, MCT oil, mushrooms, and moringa.

The launch of XOMA and the accompanying DTC e-commerce platform, provides NEXE with a sales ecosystem for its proprietary capsules. The launch will better enable NEXE to understand its customers and their tastes, manage quality control and logistics, and maintain high brand integrity, while providing customers with a great overall experience.

The ongoing global COVID-19 pandemic has forced consumers to prioritize their grocery spend taking a more active role in their personal wellness. This focus on health has increased consumer demand for functional foods and superfoods with high-quality novel ingredients. At the same time, the pandemic has accelerated the move to online DTC sales, as consumers avoid public spaces either by preference or local health ordinance.

With its experience in packaging high-quality coffee using innovative compostable materials, NEXE is well-placed to meet the important demands of the health and environmentally-conscious consumer.

About NEXE Innovations Inc.

NEXE Innovations Inc. is a leader in plant-based compostable technology and advanced materials innovation based in British Columbia, Canada. The company has developed one of the only patented, fully compostable, plant-based, single-serve coffee pods for use in existing major single-serve coffee machines. The proprietary NEXE pod is designed to reduce the significant environmental impact caused by single-serve pods (+40 billion plastic pods discarded every year). With over $30M raised (equity and government funding) to date and over five years of R&D, NEXE is well-positioned to meet the growing demand for environmentally friendly and sustainable products in the single-serve coffee sector and beyond.

Website: www.nexe.ca
Xoma Superfoods: www.xoma.ca
Youtube Channel: https://youtu.be/eGV9tKfgt5I

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this release are forward-looking statements or information, which include the proposed use of proceeds, commercialization of the NEXE PODs, including the XOMA Superfoods Brand, and increase production capacity, create other environmentally friendly compostable packaging opportunities, development of technologies, the potential of the Company’s technology, future plans, regulatory approvals and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, consumer demand for and sentiment towards the Company’s products, security threats, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the demand for its products, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, failure to obtain regulatory approval, the continued availability of capital and financing, equipment failures, litigation, increase in operating costs, the impact of Covid-19 or other viruses and diseases on the Company’s ability to operate, competition, failure of counterparties to perform their contractual obligations, government regulations, loss of key employees and consultants, and general economic, market or business conditions.  Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information.

The forward-looking statements contained in this news release are made as of the date of this news release.  Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/nexe-launches-xoma-superfoods-301205992.html

SOURCE Nexe Innovations Inc.

LOS ALAMITOS, Calif., Jan. 12, 2021 /PRNewswire/ — Today at NRF 2021: Retail’s Big Show, Epson America, Inc., a supplier of industry-leading Point of Sale (POS) solutions, is revolutionizing the POS industry once again with the introduction of the OmniLink^® TM-m50 POS thermal receipt printer, the latest addition to Epson’s growing family of intelligent OmniLink POS printers. With the continued rise in mobile and online ordering across hospitality and retail industries, merchants require solutions that enable quick, efficient, safe, and reliable transactions. Epson’s new, versatile, 3-inch compact OmniLink TM-m50 POS thermal receipt printer meets those demands with functionality and flexibility that help retailers and restaurants deliver world-class dining and shopping experiences now and into the future.

With a continued emphasis on social distancing, buying online for in-store or curbside pickup will likely trend for the foreseeable future. This migration to online business requires reliable and flexible POS solutions to enable customers to pay for their items quickly and leave. With some of the most advanced features available today, Epson’s new OmniLink TM-m50 POS thermal receipt printer was designed to accommodate these demands and is an ideal solution for customer-facing businesses of all sizes, ranging from small specialty shops, delis, bars, and fine dining to hotels, retail and restaurant chains and large department stores.

“True to our strong history of innovation and commitment to address the latest market trends and demands, we are continually evolving our POS product solutions,” said Aileen Maldonado, product manager, Business Systems, Epson America Inc. “Customers want efficiency, and they want to order online, so merchants must adapt by using the best solutions to accommodate them. The new OmniLink TM-m50 expands on the capabilities of the existing mPOS product line, keeping the compact sleek modern industrial design while increasing print speeds, reliability and expanding connectivity for traditional PC-POS systems. This is critical for today’s merchants who need their receipt printer to meet the rigorous demands of high-volume transactions.” 

The OmniLink TM-m50 combines the sleek and compact design of Epson’s mPOS receipt printer line with the intelligent features found in OmniLink receipt printers, giving merchants the best of both solutions. The 3-inch printer features a modular casing that allows easy switching from a top-load to front-load configuration, addressing issues such as space restrictions, environmental roadblocks and peripheral specifications.

A rich feature set helps merchants best serve their customers, whether they buy online to pick up in the store, use curbside pickup or order for home delivery. Providing great flexibility, the OmniLink TM-m50 can be dynamically shared by tablets, smartphones and PC-POS or cloud POS systems. With multi-interface connectivity options to help future-proof growing businesses, the printer includes built-in Ethernet and USB, Serial, Bluetooth^®, and wireless options. Key functions such as online ordering and remote printing are supported through Epson’s Server Direct Print technology. Merchants also benefit from access to the latest cloud applications via OmniLink Merchant Services, giving them more options to support their business needs.

This printer also enables transactions anywhere in the store or restaurant with iBeacon and NFC connectivity. Epson’s beacon support¹ helps mobile devices identify the nearest printer, making it ideal for POS environments where multiple users are sending data to a central printer to produce receipts, and NFC² support makes it easy to pair tablets, smartphones and other mobile devices. With a printhead life of 200 km³ and auto cutter life of 2.2 million cuts,³ customers benefit from remarkable printer reliability. Ideal for busy retail and hospitality environments, the printers can quickly print receipts at up to 350 mm/sec. In addition, innovative paper-saving technology enables environmentally conscientious merchants to reduce paper usage by up to 49 percent.⁴

The new OmniLink TM-m50 includes new features which can charge smart devices, including tablets and smartphones, offers data communication between the printer and a tablet using a single cable⁵ (cable not included), and provides network connectivity from the printer to select tablets through USB-Network-Tethering,⁶ addressing merchants’ need for reliable wired networks. These features are ideal for high-volume merchants who want to prevent disruption from their POS system going offline, possibly resulting in poor customer experiences and lost revenue.

Availability
The OmniLink TM-m50 POS thermal receipt printers will be available from Epson authorized channel partners by the end of January 2021. For additional information, visit www.epson.com/m50.

About Epson
Epson is a global technology leader dedicated to becoming indispensable to society by connecting people, things and information with its original efficient, compact and precision technologies. The company is focused on driving innovations and exceeding customer expectations in inkjet, visual communications, wearables and robotics. Epson is proud of its contributions to realizing a sustainable society and its ongoing efforts to realizing the United Nations’ Sustainable Development Goals.

Led by the Japan-based Seiko Epson Corporation, the worldwide Epson Group generates annual sales of more than JPY 1 trillion. global.epson.com/

For over 30 years, Epson’s advanced technology has been at work in millions of POS systems around the world. Today Epson’s Business Systems Division continues to bring industry-leading, open architecture, smart technologies to the point of service.

Epson America, Inc., based in Los Alamitos, Calif., is Epson’s regional headquarters for the U.S., Canada, and Latin America. To learn more about Epson, please visit: epson.com. You may also connect with Epson America on Facebook (facebook.com/Epson), Twitter (twitter.com/EpsonAmerica), YouTube (youtube.com/EpsonAmerica), and Instagram (instagram.com/EpsonAmerica).

¹ Requires the use of a beacon dongle connected to TM-m50 printer via the USB-A port. Supports only Apple® iBeacon™ compliant format. The Epson-approved dongle is Laird model BT820.
² NFC tag requires use of a device that includes NFC reader, and may require additional software.
³ Rated printhead and cutter lives are only estimates based on normal use of the printer with the following media only, with printer operated at room temperature and normal humidity: Model KT55FA: Papierfabrik August Koehler SE; Model PD160R: Oji Imaging Media Co., Ltd.; Model TF50KS-Y: NIPPON Paper Industries Co., Ltd. Epson’s statements about reliability levels are not warranties of the media or Epson’s printers, and the only warranties for printers are the limited warranty statements for each printer. See www.epson.com/testedmedia for more information on Tested Media.
⁴ Paper savings depend on the text and graphics printed on the receipt.
⁵ Feature available for iOS® devices and Android™ devices running Android 10 or later.
⁶ Only works with iOS devices.

EPSON is a registered trademark and EPSON Exceed Your Vision is a registered logomark of Seiko Epson Corporation. OmniLink is a registered trademark of Epson America. All other trademarks and/or registered trademarks are property of their respective owners. Epson disclaims any and all rights in these marks. Copyright 2021 Epson America, Inc.

View original content to download multimedia:http://www.prnewswire.com/news-releases/epson-launches-new-omnilink-pos-receipt-printer-designed-to-bring-reliability-efficiency-and-convenience-for-safe-shopping-dining-online-ordering-and-pickup-301205960.html

SOURCE Epson America, Inc.

LONDON, Jan. 12, 2021 /PRNewswire/ — CentralNic Group PLC (AIM: CNIC), the fastest-growing company in the domain name industry, with over 45 million domains using its platforms, is pleased to announce it has acquired leading corporate internet services provider, SafeBrands. An award-winning innovator and technology pioneer, SafeBrands will add its online brand protection and domain name management products and expertise to CentralNic’s industry-leading suite of digital services for businesses.

SafeBrands’ proprietary state-of-the-art internet monitoring tools and enforcement expertise have to date only been available to companies in French-speaking markets. CentralNic will make them available to companies globally, to help them protect their revenue streams in digital channels – as part of CentralNic’s global Brand Services, which currently serves clients worldwide through teams based in the US, the UK, Germany, Canada, Australia, New Zealand, and a dozen other countries.

SafeBrands’ strong presence in France, one of the largest internet services markets globally, complements BrandShelter’s leading position as a corporate registrar in Germany – positioning CentralNic as the European champion for corporate domain portfolio management and online brand protection, as well as one of the top three global leaders available to serve customers in any country.

Ben Crawford, CentralNic Group CEO, commented: “This is an important next step for CentralNic in our strategy to provide comprehensive end-to-end digital domain name and online brand protection services to corporate clients, globally. We are delighted that SafeBrands, its talented team of digital and IP protection experts, cutting-edge software and service portfolio and established business relationships, are becoming part of our Group.” 

Haydn Simpson, CentralNic’s Head of Brand Services, said: “Intellectual Property is the lifeblood of any company, creating value and differentiation, and the successful future of any brand depends on protecting it with maximum efficiency. SafeBrands’ brand protection products will help CentralNic further broaden our capabilities in this space, creating an unparalleled suite of solutions for our current and future customers.”

Charles Tiné, CEO and founder of SafeBrands, added: “In the fast-growing domain name market, this represents a fantastic opportunity for SafeBrands to join the CentralNic family with the clear ambition to create a world leader in corporate domain management, online brand protection and DNS security. We share many common values that are reflected in the many synergies between our teams and technical platforms. CentralNic’s resources and growth strategy are aligned with our ambitions and point to a very exciting future. After 23 years of organic and independent development, Frederic Guillemaut and myself are convinced to have found the perfect fit for SafeBrands’ V2.”

About CentralNic Group PLC
CentralNic (AIM: CNIC) is a global company listed on the London stock exchange that drives the growth of the global digital economy by developing and managing software platforms allowing businesses to buy subscriptions to domain names and related services, including protecting their brands online. In addition to providing core infrastructure services for the internet, CentralNic is a leader in protecting internet users through its sophisticated software, dedicated anti-abuse teams, and partnerships with such entities as the Global Cyber Alliance.

CentralNic’s Brand Services companies offer the range of domain portfolio management and brand protection services to companies around the world, from small businesses to some of the largest companies in the world. 

For more information, please visit www.centralnicgroup.com

Media contact: [email protected]

View original content:http://www.prnewswire.com/news-releases/centralnic-group-acquires-safebrands-enhances-brand-services-301205948.html

SOURCE CentralNic Group PLC